Bujalska Magdalena, Tatarkiewicz Jan, de Cordé Anna, Gumułka Stanisław Witold
Department of Pharmacodynamics, Medical University of Warsaw, Warsaw, Poland.
Pharmacology. 2008;81(2):151-7. doi: 10.1159/000110787. Epub 2007 Nov 7.
We examined a possible involvement of cyclooxygenase (COX) and nitric oxide synthase (NOS) products in hyperalgesia occurring during streptozotocin (STZ)-induced diabetes. Indomethacin and celecoxib were used as relatively selective inhibitors of COX-1 and COX-2, respectively. NOS inhibitors included: non-specific inhibitor N(G)-nitro-L-arginine and L-N(6)-(1-iminoethyl)lysine preferentially acting on inducible NOS (iNOS) as well as 7-nitroindazole relatively specific inhibitor neuronal NOS (nNOS). The above-mentioned agents, except 7-nitroindazole, suppressed hyperalgesia occurring after administration of STZ. The results of the study suggest participation of COX-1, COX-2 and iNOS, but not nNOS, in transmission of pain stimuli in STZ-induced diabetic hyperalgesia.
我们研究了环氧化酶(COX)和一氧化氮合酶(NOS)产物是否参与链脲佐菌素(STZ)诱导的糖尿病过程中出现的痛觉过敏。吲哚美辛和塞来昔布分别用作COX-1和COX-2的相对选择性抑制剂。NOS抑制剂包括:非特异性抑制剂N(G)-硝基-L-精氨酸和优先作用于诱导型NOS(iNOS)的L-N(6)-(1-亚氨基乙基)赖氨酸,以及相对特异性的神经元NOS(nNOS)抑制剂7-硝基吲唑。除7-硝基吲唑外,上述药物均抑制了STZ给药后出现的痛觉过敏。研究结果表明,COX-1、COX-2和iNOS参与了STZ诱导的糖尿病性痛觉过敏中疼痛刺激的传递,而nNOS未参与。